Akebia Therapeutics Repays $55 Million Loan in Full

By Public Technologies
  • Akebia Therapeutics repaid its $55 million BlackRock loan facility in full using proceeds from Symbiotic Capital's initial $60 million tranche.
  • The senior secured term loan facility, worth up to $140 million, closed on November 12, 2026.
  • An additional tranche of up to $80 million is available at Symbiotic Capital's discretion.
  • The facility has a 60-month maturity with interest-only payments throughout; principal is due at maturity.
  • The variable monthly interest rate equals the greater of WSJ Prime plus 4.5% or 11.5%.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akebia Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611160800PRIMZONEFULLFEED9878004) on November 16, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk